Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911341 | 0.82 | NUDT1 (0.58) | NUDT1TSHR | |
| SCHEMBL89746 | 0.82 | NUDT1 (0.36) | NUDT1TSHR | |
| SCHEMBL9918974 | 0.76 | LMNA (0.38) | LMNANUDT1PDE10A | |
| SCHEMBL27416397 | 0.75 | NUDT1 (0.41) | LMNANUDT1 | |
| SCHEMBL90083 | 0.74 | MCHR1 (0.40) | — | |
| SCHEMBL19171958 | 0.73 | LMNA (0.46) | LMNATSHRPDE10A | |
| SCHEMBL27280765 | 0.73 | HSD17B10 (0.37) | LMNANUDT1TSHR | |
| SCHEMBL12795986 | 0.68 | NUDT1 (0.34) | LMNANUDT1 | |
| SCHEMBL16647748 | 0.68 | CNR2 (0.42) | LMNATSHR | |
| SCHEMBL90167 | 0.67 | SLC6A4 (0.38) | LMNATSHREHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | LMNA 1594/4885NUDT1 281/4885TSHR 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.